Protagonist Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $56,368 | $7,437 | $4,712 | $5,546 |
Gross Profit | 55,961 | 7,437 | 4,712 | 5,546 |
EBITDA | 2,688 | -43,342 | -38,978 | -34,295 |
EBIT | 2,281 | -43,718 | -39,339 | -34,599 |
Net Income | 3,783 | -44,384 | -39,339 | -34,771 |
Net Change In Cash | 56,368 | 7,437 | 4,712 | 5,546 |
Free Cash Flow | -49,158 | -35,529 | -2,025 | -29,593 |
Cash | 193,712 | 128,390 | 113,713 | 168,543 |
Basic Shares | 70,492 | 63,573 | 63,772 | 63,511 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $46,016 | $434,433 | $60,000 | $26,581 |
Gross Profit | 44,791 | 434,433 | 60,000 | 26,581 |
EBITDA | -128,086 | 280,234 | -75,643 | -128,004 |
EBIT | -129,311 | 279,408 | -78,955 | -131,373 |
Net Income | -130,149 | 275,188 | -78,955 | -123,413 |
Net Change In Cash | 46,016 | 434,433 | 60,000 | 26,581 |
Cost of Revenue | 2,169 | |||
Free Cash Flow | 56,081 | 182,797 | -70,845 | -108,932 |
Cash | 128,390 | 97,249 | 186,727 | 125,744 |
Basic Shares | 63,573 | 65,078 | 56,763 | 49,042 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0.05 |
2025-12-31 | -$0.69 |
2025-09-30 | -$0.62 |
2025-06-30 | -$0.55 |